Doxorubicin Activates Ryanodine Receptors in Rat Lymphatic Muscle Cells to Attenuate Rhythmic Contractions and Lymph Flow

Doxorubicin is a risk factor for secondary lymphedema in cancer patients exposed to surgery or radiation. The risk is presumed to relate to its cytotoxicity. However, the present study provides initial evidence that doxorubicin directly inhibits lymph flow and this action appears distinct from its c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Pharmacol Exp Ther
Autors principals: Stolarz, Amanda J., Sarimollaoglu, Mustafa, Marecki, John C., Fletcher, Terry W., Galanzha, Ekaterina I., Rhee, Sung W., Zharov, Vladimir P., Klimberg, V. Suzanne, Rusch, Nancy J.
Format: Artigo
Idioma:Inglês
Publicat: The American Society for Pharmacology and Experimental Therapeutics 2019
Matèries:
Cardiovascular
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6815939/
https://ncbi.nlm.nih.gov/pubmed/31439806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.257592
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars